New treatments for age-related macular degeneration.
Rosenfeld
Philip J
PJ
D020533:Angiogenesis Inhibitors / Q000097:blood* / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000097:blood* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000097:blood / Q000627:therapeutic use; D000068258:Bevacizumab; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy; D011817:Rabbits; D000069579:Ranibizumab; D012016:Reference Values
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab